Compare Fidelity National Information Servcs Inc (FIS) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fidelity National Information Servcs Inc vs BIO-TECHNE Corp — how do they compare? Fidelity National Information Servcs Inc trades at $41.82 (market cap $21.24B), while BIO-TECHNE Corp trades at $71.65 (market cap $11.14B). The key difference: Fidelity National Information Servcs Inc is the larger of the two by market cap, and Fidelity National Information Servcs Inc pays the higher dividend (4.09%). Which is the better fit depends on your goals.
| FIS | TECH | |
|---|---|---|
Market Cap | $21.24B | $11.14B |
Sector | Technology | Health |
52-Week High | $81.94 | $71.48 |
52-Week Low | $37.72 | $43.31 |
Enterprise Value | $41.63B | $11.22B |
Dividend Yield | 4.09% | 0.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FIS (Fidelity National Information Services) trades at $40.58, down 3.22% on the day, with a bearish technical signal and neutral oscillators. The company shows improving fundamentals with Q1 2026 EPS beating expectations at $1.36 versus $1.29, and analyst consensus remains strong with 21 Buy ratings and a $52.57 price target. Recent business developments include winning Frankfurt International Bank as a cloud banking client and receiving industry awards for AI-embedded risk technology.
The outlook presents a value opportunity with a low P/E of 7.97 and improving profit margins, though execution risks persist from the Worldpay divestiture and net cash flow volatility. Upside potential exists if the company capitalizes on its $42 billion market opportunity in digital payments and maintains its recent earnings momentum.
Bio-Techne Corporation (TECH) trades at $71.66, near its all-time high, following Merck KGaA's announced $73 per share cash acquisition offer, representing a 24% premium. The stock shows a bullish technical trend, while fundamental metrics reveal a high valuation with a P/E of 102.12 and a net income margin of 9.05%. Recent earnings have been mixed, with Q4 2025 beating expectations but Q1 2026 missing. Analyst consensus is evenly split between Buy and Hold, with a $67.75 price target below the current offer price.
The investment outlook is dominated by the pending acquisition by Merck KGaA. The primary opportunity is the realization of the $73 per share offer, providing a clear exit near current levels. Key risks include potential deal completion delays, regulatory scrutiny, and shareholder litigation questioning the fairness of the price. Should the deal fall through, the stock faces significant downside pressure given its stretched valuation and recent earnings volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fidelity National Information Servcs Inc
Fidelity National Information Services' legacy operations provide core and payment processing services to banks, but its business has expanded over time. By acquiring Sungard in 2015, the company now provides record-keeping and other services to investment firms. With the acquisition of Worldpay in 2019, FIS now provides payment processing services for merchants and holds leading positions in the United States and United Kingdom. About a fourth of revenue is generated outside North America.
Read more on FIS →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
